Navigation Links
BioNano Genomics Announces the Adoption of Irys System by the Garvan Institute of Medical Research
Date:12/3/2013

SAN DIEGO and SYDNEY, Dec. 3, 2013 /PRNewswire/ -- BioNano Genomics announced today the Garvan Institute of Medical Research has elected to incorporate the Irys technology into their disease research programs, with particular emphasis on improving understanding of prostate cancer.  With their purchase of an Irys System, Garvan becomes the first Early Access user of the technology in Australia. 

"A complete understanding of the human genome variability and its relation to health continues to evade us," said Principal Investigator Dr. Vanessa Hayes, Petre Chair of Prostate Cancer Research at the University of Sydney and Professor of Human Comparative and Prostate Cancer Genomics at the Garvan Institute of Medical Research and The Kinghorn Cancer Centre. 

Dr. Hayes continued, "Structural variation, in particular, is a critical and abundant form of novelty in genomes that unfortunately is dramatically understudied due to the lack of suitable tools available.  Rather than generating the same type of data over and over, we are very keen to adopt new technologies that will allow us to better address the question: what are we missing? The Irys platform will have a major impact on our ability to characterize human genome variation, and we are thrilled to be the first group in Australia to adopt this new technology. It will also strengthen the Garvan Institute's capability for human genome analysis." 

The Kinghorn Cancer Centre was established in August 2012 as a joint initiative of the Garvan Institute and St Vincents & Mater Health Sydney.  The Centre's primary focus is to study the molecular biology of cancer, develop new diagnostics and therapeutics, and transition these advances into clinical practice through holistic and individualized clinical care. 

"Key to our mission," said Dr. Hayes, "is developing a much deeper understanding of the origin and progression of prostate cancer.  Structural variation is likely to be a big driver and the area that most needs to be studied.  The Irys technology will go a long way to helping us accomplish this goal."

Dr. Hayes is well known for studying ancient populations to better understand human health from a pure genomic perspective, outside of the confounding context of modern medicine. The ability to analyze such divergent genomes de novo and retain natural haplotype differences using extremely long molecule detection with Irys overcomes the limitations of traditional methods of re-sequencing and exome-targeted sequencing.

This unbiased, independent de novo capability is essential, according to Dr. Hayes, as "the reference genome is not ideal for the populations we study."

About Irys

Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary NanoChannel Arrays where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long "reads" ranging from hundreds of kilobases to a megabase, where the sample's valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.

About BioNano Genomics

Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company's platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.

www.BioNanoGenomics.com

Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.

 

 

 


'/>"/>
SOURCE BioNano Genomics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioNano Genomics Launches Irys In Europe At ESHG 2013
2. BioNano Genomics führt auf ESHG 2013 Irys in Europa ein
3. BioNano Genomics lanza Irys en Europa en ESHG 2013
4. BIT Group Partners with BioNano Genomics to Produce Revolutionary Genomics Platform
5. BioNano Genomics Announces The Purchase Of The Irys System By The Chinese Academy Of Sciences And Tel Aviv University
6. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
7. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
8. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
11. First Plant Genomics Yield Technology Progresses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... To acquire information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity ... rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, the ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):